LIFE - aTyr Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

aTyr Pharma, Inc.

3545 John Hopkins Court
Suite 250
San Diego, CA 92121
United States
858 731 8389
http://www.atyrpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Sanjay S. ShuklaPres, CEO & Director460.08kN/A1972
Ms. Jill M. BroadfootChief Financial Officer361.59kN/A1962
Ms. Nancy E. Denyes KruegerGen. Counsel & Corp. Sec.347.93kN/A1968
Xiang-Lei Yang Ph.D.FounderN/AN/AN/A
Mr. Peter VilligerVP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for regulating immune engagement in interstitial lung diseases. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was founded in 2005 and is headquartered in San Diego, California.

Corporate Governance

aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.